Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 726

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 726
---
, DECEMBER 31, 2024                                    |     |          206,452 |        |     | $ |  166,353 |        |     |     3,159,535 |     | $ | 2,740,958 |     | $          | 72,820,671 |   |     | $            | (74,430,474 | ) |     | $             |  108,853 |   |     | $     |   1,406,361 |   |

Adjusted for the effect of a 1 -to-40reverse share split that was effective September 27, 2024 (See note 2). The accompanying notes are an integral part of these consolidated financial statements.

Annex F-6

NLS PHARMACEUTICS LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

| Cash Flows From Operating Activities:                                                   |     | For the Years Ended December 31, 
 2024                             |            |   |     | 2023 |             |   |     | 2022 |             |   |
|:----------------------------------------------------------------------------------------|:----|:---------------------------------|-----------:|:--|:----|:-----|------------:|:--|:----|:-----|------------:|:--|
| Net loss                                                                                |     | $                                | (1,980,810 | ) |     | $    | (12,172,029 | ) |     | $    | (16,495,680 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:             |     |                                  |            |   |     |      |             |   |     |      |             |   |
| Periodic pension costs                                                                  |     |                                  |      6,239 |   |     |      |      59,526 |   |     |      |     (34,142 | ) |
| Depreciation expense                                                                    |     |                                  |      3,321 |   |     |      |      11,408 |   |     |      |      11,408 |   |
| Stock-based compensation                                                                |     |                                  |    125,644 |   |     |      |     164,906 |   |     |      |      22,730 |   |
| Other income due to the termination of EF License Agreement                             |     |